The Chemopreventive Agent Development Research Group (CADRG) promotes and supports research on cancer preventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to intercept the carcinogenic process by identifying and developing preventative agents with the potential to block, reverse, or delay the early stages of cancer. In addition, the group supports research on clinically translatable biomarkers that can be used to monitor tumor initiation and progression or assess efficacy of preventive interventions.
Read more About the Chemopreventive Agent Development Research Group.
News and Events
DCP Participation at American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024
Date Posted: March 12, 2024
DCP/PREVENT-funded Project Presentations at the 2024 AACR Annual Meeting
Date Posted: March 12, 2024
Research Highlights: Investigating Ways to Reduce and Avoid Side Effects of Medications for Breast Cancer Risk Reduction
Date Posted: December 15, 2023
Immune Interception Approaches for Individuals at Risk for Pancreatic Cancer
Date Posted: December 13, 2023
Research Highlights: Repurposing Common Medications to Prevent Cancer
Date Posted: September 11, 2023